98%
921
2 minutes
20
Psoriatic arthritis (PsA) is a chronic, inflammatory disease with heterogeneous clinical features. The pathogenesis of PsA involves a complex interplay of genetic, immunologic, and environmental factors, leading to the activation of the immune system and subsequent inflammation. Over the past decade, the understanding of the immune mechanisms underlying PsA has advanced significantly, particularly regarding the role of the interleukin-23/T helper 17 pathway in the disease process. Guselkumab, a novel IL-23 inhibitor, has emerged as a promising therapeutic option for PsA, offering an alternative to conventional therapies and other biologics. This review aims to summarize the current evidence on the efficacy, safety, and clinical utility of guselkumab in the treatment of PsA.
Download full-text PDF |
Source |
---|
JAMA Netw Open
September 2025
Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla.
Importance: Janus kinase (JAK) inhibitors are highly effective medications for several immune-mediated inflammatory diseases (IMIDs). However, safety concerns have led to regulatory restrictions.
Objective: To compare the risk of adverse events with JAK inhibitors vs tumor necrosis factor (TNF) antagonists in patients with IMIDs in head-to-head comparative effectiveness studies.
JAMA Netw Open
September 2025
Department of Psychiatry, Psychosomatics, and Psychotherapy, University of Lübeck, Lübeck, Germany.
Importance: Patients with inflammatory rheumatic diseases (IRDs) frequently experience psychological distress; however, access to psychological support remains limited.
Objective: To investigate the effectiveness of a digital psychological intervention for individuals with IRDs.
Design, Setting, And Participants: Participants aged 18 years or older were recruited across Germany between February 22 and June 4, 2024, if they had been diagnosed with rheumatoid arthritis, psoriatic arthritis, or systemic lupus erythematosus and reported psychological distress and reduced quality of life.
Rheumatol Int
September 2025
Division of Rheumatology and Immunology, Department of PMR, , Sakarya University School of Medicine, Sakarya, Turkey.
To identify clinical and demographic predictors associated with the timing of transition from psoriasis (PsO) to psoriatic arthritis (PsA), and to compare the characteristics of patients with concurrent PsO-PsA onset versus those with prolonged transition. A multi-center, observational study was conducted using data from the Turkish League Against Rheumatism (TLAR) network including PsA patients fulfilling CASPAR criteria. Patients were categorized into two groups: Group 1 (concurrent PsO and PsA onset within ± 1 year) and Group 2 (prolonged transition to PsA, > 1 year after PsO).
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
Department of Health Statistics, School of Public Health, Shandong Second Medical University, Weifang, Shandong, China.
Both psoriasis and autoimmune thyroid diseases are characterized by chronic inflammation. The previous studies indicated a potential association between psoriasis and autoimmune thyroid diseases. However, the direction and nature of these relationships remain unclear.
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
Jingjiang People's Hospital Affiliated to Yangzhou University, Taizhou, Jiangsu, China.
Previous epidemiological research has shown that immune cells have a significant impact on the progression and development of psoriatic arthritis (PsA). However, the causal relationship between immune cell characteristics and PsA remains uncertain. A bidirectional 2-sample Mendelian randomization analysis was conducted, using data from publicly available genome-wide association studies.
View Article and Find Full Text PDF